CEO Paul Bolno was paid $12,277,916 in fiscal year 2025, ↑ up 187.4% from fiscal year 2024, the 71st percentile of its disclosed peer group (SEC filing 0001193125-26-421806 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$12,277,916 ↑ Paul Bolno total, FY2025 | 71st CEO pay percentile vs peers | — CEO-to-median pay ratio | 99.25% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
WVE's next annual pay disclosure, estimated February 4, 2028.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Bolno | $700,000 | $0 | $1,420,540 | $9,506,300 | $614,250 | $0 | $36,826 | $12,277,916 |
| President and Chief Executive Officer | ||||||||
| Kyle Moran | 520,100 | 0 | 493,080 | 2,395,588 | 331,759 | 0 | 12,822 | 3,753,349 |
| Chief Financial Officer | ||||||||
| Chandra Vargeese | 502,200 | 0 | 434,380 | 2,129,411 | 320,341 | 0 | 14,064 | 3,400,396 |
| Chief Technology Officer, Head of Platform Discovery Sciences | ||||||||
| Christopher Francis | 451,400 | 0 | 293,500 | 1,435,451 | 274,226 | 0 | 11,310 | 2,465,887 |
| Chief Strategy Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Bolno | $12,277,916 | $4,272,299 | $3,874,300 | ↑ +8,005,617 |
| Kyle Moran | 3,753,349 | 1,917,381 | 1,697,072 | ↑ +1,835,968 |
| Chandra Vargeese | 3,400,396 | 1,888,563 | 1,783,339 | ↑ +1,511,833 |
| Christopher Francis | 2,465,887 | 1,566,422 | 1,527,469 | ↑ +899,465 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Wave Life Sciences's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper WVE reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses WVE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named WVE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Christopher Francis | SVP | $2,465,887 |
| Chandra Vargeese | CTO | $3,400,396 |
| Kyle Moran | CFO | $3,753,349 |
| Paul Bolno | CEO | $12,277,916 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Adrian Rawcliffe | Independent Director | $534,975 |
| Aik Na Tan | Independent Director | $989,933 |
| Christian Henry | Chair of the Board | $565,600 |
| Gregory L. Verdine, Ph.D | Director | — |
| Heidi L. Wagner, J.D | Independent Director | $529,975 |
| Ken Takanashi | Independent Director | $514,975 |
| Mark H. N. Corrigan, M.D | Independent Director | $539,975 |
| Peter Kolchinsky, Ph.D | Independent Director | — |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kyle Moran | OPTION | 2025-02-04 | — | — | 252,000 | — | $2,395,588 |
| Kyle Moran | RSU | 2025-02-04 | — | — | 42,000 | — | 493,080 |
| Paul Bolno | OPTION | 2025-02-04 | — | — | 1,000,000 | — | 9,506,300 |
| Paul Bolno | RSU | 2025-02-04 | — | — | 121,000 | — | 1,420,540 |
| Christopher Francis | OPTION | 2025-02-04 | — | — | 151,000 | — | 1,435,451 |
| Christopher Francis | RSU | 2025-02-04 | — | — | 25,000 | — | 293,500 |
| Chandra Vargeese | RSU | 2025-02-04 | — | — | 37,000 | — | 434,380 |
| Chandra Vargeese | OPTION | 2025-02-04 | — | — | 224,000 | — | 2,129,411 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kyle Moran | $493,080 | $0 | $2,395,588 | 0.0% |
| Paul Bolno | 1,420,540 | 0 | 9,506,300 | 0.0% |
| Christopher Francis | 293,500 | 0 | 1,435,451 | 0.0% |
| Chandra Vargeese | 434,380 | 0 | 2,129,411 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chandra Vargeese | RSU | 50,000 | — | $850,000 |
| Paul Bolno | RSU | 92,500 | — | 1,572,500 |
| Chandra Vargeese | RSU | 27,750 | — | 471,750 |
| Paul Bolno | RSU | 90,750 | — | 1,542,750 |
| Christopher Francis | Option | 161,100 | 3.87 | — |
| Paul Bolno | Option | 37,500 | 3.14 | — |
| Paul Bolno | Option | 1,000,000 | 11.74 | — |
| Paul Bolno | Option | 10,938 | 3.14 | — |
| Chandra Vargeese | Option | 224,000 | 11.74 | — |
| Paul Bolno | RSU | 31,500 | — | 535,500 |
| Paul Bolno | RSU | 15,000 | — | 255,000 |
| Chandra Vargeese | Option | 92,313 | 4.75 | — |
| Christopher Francis | Option | 9,375 | 3.14 | — |
| Christopher Francis | RSU | 32,500 | — | 552,500 |
| Chandra Vargeese | Option | 203,457 | 3.87 | — |
| Christopher Francis | Option | 76,469 | 4.75 | — |
| Christopher Francis | RSU | 18,750 | — | 318,750 |
| Paul Bolno | Option | 240,938 | 4.75 | — |
| Paul Bolno | Option | 567,338 | 3.87 | — |
| Paul Bolno | Option | 85,219 | 4.75 | — |
| Paul Bolno | Option | 208,969 | 3.87 | — |
| Chandra Vargeese | Option | 12,500 | 3.14 | — |
| Paul Bolno | Option | 252,000 | 11.74 | — |
| Christopher Francis | Option | 151,000 | 11.74 | — |
Our Compensation Committee regularly reviews the elements of the individual compensation packages for our Chief Executive Officer and our other executive officers to achieve the following primary objectives: • Attract, retain and motivate superior executive talent across all areas of our business; • Provide incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value, which we seek to achieve through the discovery, development and potential commercialization of transformative medicines; • Ensure the majority of compensation is performance-based and “at-risk”; and • Align our executive officers’ interests with those of our stockholders through long-term incentives linked to specific performance.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-08-05 | 129,648,036 | 977,466 | 15,614 | 99.25% | Passed |
| 2024 | 2024-08-06 | 94,163,361 | 356,573 | 18,064 | 99.62% | Passed |
| 2023 | 2023-08-01 | 79,211,157 | 150,975 | 1,130,599 | 99.81% | Passed |
| 2022 | 2022-08-09 | 51,160,648 | 13,821,016 | 17,273 | 78.73% | Passed |
| 2021 | 2021-08-10 | 33,669,973 | 249,754 | 12,654 | 99.26% | Passed |
| 2020 | 2020-08-12 | 24,128,237 | 3,141,318 | 675 | 88.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-08-05 | 99.25%a |
| 2024 | 2024-08-06 | 99.62%b |
| 2023 | 2023-08-01 | 99.81%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Aik Na TanIndependent · Audit | $51,875 | $205,867 | $732,191 | — | — | $989,933 |
| Christian HenryIndependent · Board Chair · Audit · Compensation (Chair) | 100,000 | 102,934 | 362,666 | — | — | 565,600 |
| Mark H. N. Corrigan, M.DIndependent · Audit · Nominating and Corporate Governance · Research and Development (Chair) | 74,375 | 102,934 | 362,666 | — | — | 539,975 |
| Adrian RawcliffeIndependent · Audit (Chair) · Compensation | 69,375 | 102,934 | 362,666 | — | — | 534,975 |
| Heidi L. Wagner, J.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | 64,375 | 102,934 | 362,666 | — | — | 529,975 |
| Peter KolchinskyIndependent · Partial-year service | 49,375 | 102,934 | 362,666 | — | — | 514,975 |
| Gregory L. VerdineIndependent · Partial-year service | 49,375 | 102,934 | 362,666 | — | — | 514,975 |
| Ken TakanashiIndependent · Nominating and Corporate Governance | 49,375 | 102,934 | 362,666 | — | — | 514,975 |
| Paul B. Bolno, M.D., MBAEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $508,125 |
| Equity awards (grant-date value) | $926,405 |
| All other compensation | $0 |
| Total cost of the board | $1,434,530 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Wave Life Sciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Wave Life Sciences.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 4 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 5 | Wave Life Sciences | 2025 | Paul Bolno | 700,000 | 1,420,540 | 9,506,300 | 614,250 | 12,277,916 |
| 6 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 7 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 8 | Beam Therapeutics, Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 9 | Intellia Therapeutics, Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 10 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 11 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 12 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 13 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
| 14 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 15 | Arcturus Therapeutics Holdings, Inc. | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Wave Life Sciences | 135% | not disclosed | not disclosed | Aon Consulting Inc. |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Arcturus Therapeutics Holdings, Inc. | not disclosed | Options 100 | not disclosed | not disclosed |
| Arrowhead Pharmaceuticals, Inc. | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| Beam Therapeutics, Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Intellia Therapeutics, Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Paul Bolno | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation”. As printed: 12,277,916. Filing ↗machine: r2 · c27 · span 338591–338601 |
| 2 | Section 01, Kyle Moran | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation”. As printed: 3,753,349. Filing ↗machine: r5 · c27 · span 344791–344800 |
| 3 | Section 01, Chandra Vargeese | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation”. As printed: 3,400,396. Filing ↗machine: r8 · c27 · span 350978–350987 |
| 4 | Section 01, Christopher Francis | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation”. As printed: 2,465,887. Filing ↗machine: r11 · c27 · span 357329–357338 |
| 5 | Section 03, Kyle Moran OPTION | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 378511–378520 |
| 6 | Section 03, Kyle Moran RSU | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 376829–376836 |
| 7 | Section 03, Paul Bolno OPTION | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Paul Bolno RSU | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 03, Christopher Francis OPTION | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 389093–389102 |
| 10 | Section 03, Christopher Francis RSU | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 387411–387418 |
| 11 | Section 03, Chandra Vargeese RSU | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 382131–382138 |
| 12 | Section 03, Chandra Vargeese OPTION | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 383838–383847 |
| 13 | Section 08, Aik Na Tan | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 989,933. Filing ↗machine: span 578750–578757 |
| 14 | Section 08, Christian Henry | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 565,600. Filing ↗machine: span 571947–571954 |
| 15 | Section 08, Mark H. N. Corrigan, M.D | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 539,975. Filing ↗machine: span 573294–573301 |
| 16 | Section 08, Adrian Rawcliffe | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 534,975. Filing ↗machine: span 576058–576065 |
| 17 | Section 08, Heidi L. Wagner, J.D | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 529,975. Filing ↗machine: span 581459–581466 |
| 18 | Section 08, Peter Kolchinsky | DEF 14A | — | — | Section “Director Compensation”. As printed: 514,975. |
| 19 | Section 08, Gregory L. Verdine | DEF 14A | — | — | Section “Director Compensation”. As printed: 514,975. |
| 20 | Section 08, Ken Takanashi | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 514,975. Filing ↗machine: span 577418–577425 |
| 21 | Section 08, Paul B. Bolno, M.D., MBA | DEF 14A | 2026-10-14 | 0001193125-26-421806 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 06, 2025 vote | Form 8-K | 2025-08-11 | 0001193125-25-178083 | Item 5.07 · say-on-pay result. As reported: 99.25% (votes for as printed: 129,648,036). Filing ↗ |
| 23 | Section 06, 2024 vote | Form 8-K | 2024-08-12 | 0001193125-24-199020 | Item 5.07 · say-on-pay result. As reported: 99.62% (votes for as printed: 94,163,361). Filing ↗ |
| 24 | Section 06, 2023 vote | Form 8-K | 2023-08-07 | 0001193125-23-205066 | Item 5.07 · say-on-pay result. As reported: 99.81% (votes for as printed: 79,211,157). Filing ↗ |
| 25 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 26 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 27 | Section 09b board cost (computed) | Computed | — | — | Cash 508,125 + equity 926,405 + all other 0 = 1,434,530, summed across the director compensation table rows.machine: formula: Σ = 1,434,530 |
| 28 | Stoke Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170362 | CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. Filing ↗machine: r2 · c31 · span 335841–335851 |
| 29 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 30 | Avidity Biosciences, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001599901-25-000092 | CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. Filing ↗machine: r2 · c48 · span 430390–430400 |
| 31 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 32 | Wave Life Sciences (subject), Section 10b CEO total | DEF 14A | 2026-10-14 | 0001193125-26-421806 | CEO total compensation as printed in Wave Life Sciences's own proxy. As printed: 12,277,916. Filing ↗machine: r2 · c27 · span 338591–338601 |
| 33 | Arrowhead Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 34 | Verve Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-25 | 0000950170-25-058325 | CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442 |
| 35 | Beam Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics, Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 36 | Intellia Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197283 | CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299 |
| 37 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 38 | Prime Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 39 | Editas Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001650664-26-000037 | CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464 |
| 40 | Dyne Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173655 | CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. Filing ↗machine: r3 · c24 · span 816239–816248 |
| 41 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 42 | Arcturus Therapeutics Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193805-26-000507 | CEO total compensation as printed in Arcturus Therapeutics Holdings, Inc.'s own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919 |
| 43 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 44 | Section 10a, Avidity Biosciences, Inc. reciprocity | DEF 14A | — | 0001599901-25-000092 | Avidity Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 45 | Section 10a, Arcturus Therapeutics Holdings, Inc. reciprocity | DEF 14A | — | 0001193805-26-000507 | Arcturus Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 46 | Section 10a, Beam Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 47 | Section 10a, Editas Medicine, Inc. reciprocity | DEF 14A | — | 0001650664-26-000037 | Editas Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 48 | Section 10a, Intellia Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-197283 | Intellia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 49 | Section 10a, Dyne Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-173655 | Dyne Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 50 | Section 10a, Stoke Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-170362 | Stoke Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 51 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 52 | Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 53 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |
| 54 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Wave Life Sciences. Filing ↗ |